Online Behavioral Weight Loss for Obesity
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be taking weight-loss medication to participate.
What data supports the effectiveness of this treatment for obesity?
Is online behavioral weight loss treatment safe for humans?
How does the online behavioral weight loss treatment differ from other obesity treatments?
The online behavioral weight loss treatment, Rx Weight Loss, is unique because it is delivered entirely over the internet, allowing for greater accessibility and reach. It includes interactive features and counselor contact to enhance engagement and weight loss outcomes, which are not typically part of traditional in-person programs.14589
What is the purpose of this trial?
Obesity disproportionately impacts sexual minority women. Behavioral weight loss programs are the gold standard treatment for mild to moderate obesity. The investigators have developed an online behavioral weight loss program that is effective, low-cost, and highly scalable. However, existing research suggests that tailoring treatment to address 3 well-established weight loss barriers in sexual minority women will be critical for maximizing the relevance and efficacy of behavioral weight loss for this group. In the Preparation Phase of this K23, the investigators developed 3 novel treatment components targeting sexual minority women's weight loss barriers (i.e., minority stress, low social support, and negative body image), the investigators piloted the program among sexual minority women of higher weight, and the investigators conducted individual qualitative interviews to elicit feedback on the intervention's acceptability, cultural relevance, usability, and feasibility, and this feedback was used to refine the program.In the Optimization Phase of this K23 (the current phase), 88 women will receive 12 weeks of Rx Weight Loss and will be randomized to receive 0-3 tailored components in a full factorial design with 23 (8) distinct combinations of components. Novel components that increase mean weight loss (by ≥2%) or the proportion of women achieving clinically meaningful weight loss (by ≥10%) at 6 months will be retained in a finalized obesity treatment package that the investigators will evaluate in a future randomized controlled trial (RCT) (Evaluation Phase). The aims of this study are to:Aim 2A (Optimization): Use a factorial experiment to determine how 3 novel components impact mean weight loss and the proportion of women achieving a 5+% weight loss at 6 months.Aim 2B (Mediation): Clarify how tailored components impact weight loss by testing hypothesized mechanisms of action (i.e., coping with stress, perceived social support, weight and shape concerns).This project will tailor and optimize an evidence-based online behavioral obesity treatment to enhance weight loss outcomes in sexual minority women.
Eligibility Criteria
This trial is for sexual minority women aged 18-70 with a BMI of 25-50 who want to lose weight. Participants must be assigned female at birth, identify as female and have a minority sexual orientation (e.g., lesbian, bisexual). They need regular internet access, haven't lost significant weight recently (>5% in past 6 months), speak English fluently, and can do moderate exercise.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 12 weeks of Rx Weight Loss and are randomized to receive 0-3 tailored components in a full factorial design
Follow-up
Participants are monitored for weight loss outcomes and adherence to the program
Treatment Details
Interventions
- Behavioral weight loss intervention (Online; Rx Weight Loss)
- Minority stress intervention
- Negative body image intervention
- Social support intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Miriam Hospital
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator